739 related articles for article (PubMed ID: 29578360)
1. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
2. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever.
Ugurlu S; Ergezen B; Egeli BH; Selvi O; Ozdogan H
Rheumatology (Oxford); 2020 Dec; 59(12):3892-3899. PubMed ID: 32556219
[TBL] [Abstract][Full Text] [Related]
5. Interventions for reducing inflammation in familial Mediterranean fever.
Yin X; Tian F; Wu B; Xu T
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD010893. PubMed ID: 35349164
[TBL] [Abstract][Full Text] [Related]
6. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
Sargin G; Kose R; Senturk T
Sao Paulo Med J; 2019 May; 137(1):39-44. PubMed ID: 31116269
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever.
Ugurlu S; Hacioglu A; Adibnia Y; Hamuryudan V; Ozdogan H
Orphanet J Rare Dis; 2017 May; 12(1):105. PubMed ID: 28558744
[TBL] [Abstract][Full Text] [Related]
8. Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients.
Varan O; Kucuk H; Babaoglu H; Atas N; Salman RB; Satis H; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Clin Rheumatol; 2019 Apr; 38(4):1125-1130. PubMed ID: 30535829
[TBL] [Abstract][Full Text] [Related]
9. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure.
Stankovic Stojanovic K; Delmas Y; Torres PU; Peltier J; Pelle G; Jéru I; Colombat M; Grateau G
Nephrol Dial Transplant; 2012 May; 27(5):1898-901. PubMed ID: 21931121
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study.
Mirioglu S; Dirim AB; Bektas M; Demir E; Tor YB; Ozluk Y; Kilicaslan I; Oto OA; Yalcinkaya Y; Caliskan Y; Artim-Esen B; Yazici H; Inanc M; Turkmen A; Gul A; Sever MS
Nephrol Dial Transplant; 2023 May; 38(5):1327-1336. PubMed ID: 36542475
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever.
Hamanoue S; Suwabe T; Hoshino J; Sumida K; Mise K; Hayami N; Sawa N; Takaichi K; Fujii T; Ohashi K; Yazaki M; Ikeda S; Ubara Y
Mod Rheumatol; 2016 Jul; 26(4):610-3. PubMed ID: 25619282
[TBL] [Abstract][Full Text] [Related]
12. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever.
Erkilet HK; Gezgin Yildirim D; Esmeray P; Söylemezoğlu O
Pediatr Int; 2023; 65(1):e15588. PubMed ID: 37658625
[TBL] [Abstract][Full Text] [Related]
15. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
16. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
Karabulut Y; Gezer HH; Duruöz MT
Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
[TBL] [Abstract][Full Text] [Related]
17. IL-1 blockers together with colchicine may be administered as first line therapy in familial Mediterranean fever with amyloidosis.
Tezcan ME
Med Hypotheses; 2019 Sep; 130():109269. PubMed ID: 31383341
[TBL] [Abstract][Full Text] [Related]
18. On demand use of anakinra for attacks of familial Mediterranean fever (FMF).
Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Clin Rheumatol; 2019 Feb; 38(2):577-581. PubMed ID: 30062447
[TBL] [Abstract][Full Text] [Related]
19. Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients.
Akar S; Cetin P; Kalyoncu U; Karadag O; Sari I; Cınar M; Yilmaz S; Onat AM; Kisacik B; Erden A; Balkarli A; Kucuksahin O; Oner SY; Senel S; Tufan A; Direskeneli H; Oksuz F; Pehlivan Y; Bayindir O; Keser G; Aksu K; Omma A; Kasifoglu T; Unal AU; Yildiz F; Balci MA; Yavuz S; Erten S; Ozgen M; Sayarlıoglu M; Dogru A; Yildirim G; Oner FA; Tezcan ME; Pamuk ON; Onen F
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1090-1094. PubMed ID: 28992387
[TBL] [Abstract][Full Text] [Related]
20. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
Front Immunol; 2020; 11():971. PubMed ID: 32670263
[No Abstract] [Full Text] [Related]
[Next] [New Search]